Wall Street Analysts Believe Revolution Medicines (RVMD) Could Rally 90.58%: Here's is How to Trade
The average of price targets set by Wall Street analysts indicates a potential upside of 90.6% in Revolution Medicines (RVMD). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Revolution Medicines: Positioning Itself To Capture One Of The Largest Cancer Targets In History
Revolution Medicines is advancing a groundbreaking pan-RAS inhibitor pipeline, targeting historically undruggable mutations in tough cancers like pancreatic and lung. Early clinical data for daraxonrasib and zoldonrasib show strong efficacy and tolerability, sparking excitement among oncologists and analysts alike. Despite a robust cash position, RVMD's high burn rate and lofty valuation increase risk and sensitivity to setbacks, making entry timing challenging.
Revolution Medicines, Inc. (RVMD) Q1 2025 Earnings Call Transcript
Revolution Medicines, Inc. (NASDAQ:RVMD ) Q1 2025 Earnings Conference Call May 7, 2025 4:30 PM ET Company Participants Ryan Asay - Senior Vice President-Corporate Affairs Mark Goldsmith - Chairman and Chief Executive Officer Steve Kelsey - President-Research and Development Wei Lin - Chief Medical Officer Jack Anders - Chief Financial Officer Conference Call Participants Michael Schmidt - Guggenheim Marc Frahm - TD Cowen Eric Joseph - J.P. Morgan Jonathan Chang - Leerink Partners Kelly Shi - Jefferies Ellie Merle - UBS Operator Good day, and thank you for standing by.
Revolution Medicines, Inc. (RVMD) Q4 2024 Earnings Call Transcript
Revolution Medicines, Inc. (NASDAQ:RVMD ) Q4 2024 Earnings Conference Call February 26, 2025 4:30 PM ET Company Participants Ryan Asay - Senior Vice President-Corporate Affairs Mark Goldsmith - Chairman and Chief Executive Officer Jack Anders - Chief Financial Officer Steve Kelsey - President-Research and Development Wei Lin - Chief Medical Officer Conference Call Participants Eric Joseph - J.P. Morgan Marc Frahm - TD Cowen Michael Schmidt - Guggenheim Ben Burnett - Stifel Laura Prendergast - Raymond James Jay Olson - Oppenheimer Joe Catanzaro - Piper Sandler Poorna Kannan - Needham & Company Alex Bouilloux - Barclays Bank Operator Good day, and thank you for standing by.
Does Revolution Medicines (RVMD) Have the Potential to Rally 74.05% as Wall Street Analysts Expect?
The mean of analysts' price targets for Revolution Medicines (RVMD) points to a 74.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Revolution Medicines (RVMD) Loses -7% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Revolution Medicines (RVMD) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Revolution Medicines: Risky Buy On Recent Share Price Dip
Revolution Medicines' stock has surged over 30% since April, driven by promising clinical data for its lead asset, RMC-6236, targeting RAS-mutated cancers. RMC-6236 shows best-in-class efficacy in PDAC, with potential expansion into NSCLC and CRC, positioning it as a potential new standard of care. Despite a recent stock dip due to a $600m public offering, Revolution's robust cash position and promising pipeline offer significant long-term potential.
Revolution Medicines, Inc. (RVMD) Q3 2024 Earnings Call Transcript
Revolution Medicines, Inc. (RVMD) Q3 2024 Earnings Call Transcript
Revolution Medicines, Inc. (RVMD) Q2 2024 Earnings Call Transcript
Revolution Medicines, Inc. (NASDAQ:RVMD ) Q2 2024 Earnings Conference Call August 7, 2024 4:30 PM ET Company Participants Ryan Asay - Senior Vice President of Corporate Affairs Mark Goldsmith - Chairman and Chief Executive Officer Jack Anders - Chief Financial Officer Steve Kelsey - President of R&D Wei Lin - Chief Medical Officer Conference Call Participants Marc Frahm - TD Cowen Michael Schmidt - Guggenheim Eric Joseph - JPMorgan Jonathan Chang - Leerink Partners Chris Shibutani - Goldman Sachs Eliana Merle - UBS Alec Stranahan - Bank of America Kelly Shi - Jefferies Jay Olson - Oppenheimer Laura Prendergast - Raymond James Joseph Catanzaro - Piper Sandler Operator Good day and thank you for standing by. Welcome to Revolution Medicine's Q2 2024 Earnings Conference Call.
Revolution Medicines (RVMD) Moves 11.0% Higher: Will This Strength Last?
Revolution Medicines (RVMD) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
